1280206-16-7

Basic information

• Product Name: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile
• Synonyms: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile
• CAS NO: 1280206-16-7
• Molecular Weight: 277.12
• Mol File: 1280206-16-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile(1280206-16-7)
• EPA Substance Registry System: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile(1280206-16-7)

Safety Data

• Hazardous Substances Data: 1280206-16-7(Hazardous Substances Data)

Upstream product

• 1280206-15-6 4-bromomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole 
• 1280205-98-2 (5-(4-bromophenyl)-3-methylisoxazole-4-yl)methanol 
• 1228689-61-9 methyl 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylate 
• 85963-90-2 methyl 2-(4-bromobenzoyl)-3-oxo-butanoate 

Downstream Products

• 1280206-14-5 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid 
• 1280206-18-9 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid ethyl ester 
• 1280732-36-6 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid hydrazide 
• 1280732-37-7 2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-5-phenyl-[1,3,4]oxadiazole 
• 1280206-19-0 2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol 
• 1280206-49-6 Methanesulfonic acid 2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethyl ester 
• 1280206-50-9 4-(2-benzylsulfanyl-ethyl)-5-(4-bromo-phenyl)-3-methyl-isoxazole 
• 1280206-58-7 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid benzyl ester 

Relevant articles and documents

POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.